N

Nordic Nanovector ASA
OSE:NANOV

Watchlist Manager
Nordic Nanovector ASA
OSE:NANOV
Watchlist
Price: 1.158 NOK -1.86% Market Closed
Market Cap: 134.4m NOK

Nordic Nanovector ASA
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nordic Nanovector ASA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
N
Nordic Nanovector ASA
OSE:NANOV
Cash from Operating Activities
-kr409.1m
CAGR 3-Years
0%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Cash from Operating Activities
-kr35.6m
CAGR 3-Years
26%
CAGR 5-Years
11%
CAGR 10-Years
3%
Arcticzymes Technologies ASA
OSE:AZT
Cash from Operating Activities
kr10.6m
CAGR 3-Years
-46%
CAGR 5-Years
-23%
CAGR 10-Years
9%
N
Nykode Therapeutics ASA
OSE:NYKD
Cash from Operating Activities
-$35m
CAGR 3-Years
N/A
CAGR 5-Years
-17%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Cash from Operating Activities
-kr44.5m
CAGR 3-Years
52%
CAGR 5-Years
37%
CAGR 10-Years
7%
Zelluna ASA
OSE:ZLNA
Cash from Operating Activities
-kr162.1m
CAGR 3-Years
-4%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
No Stocks Found

Nordic Nanovector ASA
Glance View

Market Cap
134.4m NOK
Industry
Biotechnology

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 40 full-time employees. The company went IPO on 2014-07-07. The company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). The company is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. The company has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.

NANOV Intrinsic Value
Not Available
N

See Also

What is Nordic Nanovector ASA's Cash from Operating Activities?
Cash from Operating Activities
-409.1m NOK

Based on the financial report for Dec 31, 2022, Nordic Nanovector ASA's Cash from Operating Activities amounts to -409.1m NOK.

What is Nordic Nanovector ASA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-10%

Over the last year, the Cash from Operating Activities growth was -1%.

Back to Top